STAT Plus: Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and calls has predictably returned. To cope, yes, we are quaffing cups of stimulation — our flavor at the moment is mocha nut fudge — and invite you to join us. And why not? The neurons can use all the help they can get. Meanwhile, here are a few tidbits to help you on your journey. Hope your day is successful and please do keep in touch. …
Many of the nation’s largest drug makers and distributors failed to implement even the most basic systems to halt suspicious drug orders as the opioid epidemic came into sharp focus, The Wall Street Journal writes, citing a court filing. The motion by lawyers for two Ohio counties alleges companies failed to analyze potentially suspicious orders until after they had shipped, applied rudimentary controls on excessive sales that were easy for bad actors to game, and handed the job of halting shady orders to sales departments incentivized to keep pills moving.
